ENTA

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) on May 9 and set a price target of $130.00. The company's shares closed last Tuesday at $56.38. According to TipRanks.com, Skorney 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.6% and a 38.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and VistaGen Therapeutics. Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $82.86, implying a 49.5% upside from current levels.
https://www.tipranks.com/news/blurbs/robert-w-baird-keeps-their-buy-rating-on-enanta-pharmaceuticals-enta?utm_source=advfn.com&utm_medium=referral